Skip to main content
Jinyu Bio-Technology Co.,Ltd. logo

Jinyu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 600201 ISIN · CNE000000Y37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,776 across all filing types
Latest filing 2022-04-22 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 600201

About Jinyu Bio-Technology Co.,Ltd.

http://jinyubiotech.com/

Jinyu Bio-Technology Co., Ltd. focuses on the research, development, and manufacturing of veterinary biological products and pharmaceuticals. The company is a prominent supplier of animal vaccines, particularly specializing in Foot-and-Mouth Disease (FMD) vaccines, brucellosis vaccines, and solutions for swine and poultry diseases. It utilizes advanced biotechnology platforms, including large-scale suspension culture and high-efficiency purification processes, to produce high-titer, high-purity biologicals. The organization operates sophisticated research facilities and Biosafety Level 3 (P3) laboratories to support the development of diagnostic reagents and preventive treatments. Its operations center on enhancing animal health through scientific innovation, providing comprehensive disease control strategies for the global livestock industry and large-scale agricultural operations.

Recent filings

Filing Released Lang Actions
金宇生物技术股份有限公司关于以集中竞价交易方式首次回购公司股份暨回购比例达到1%的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from a company about its progress in repurchasing its own shares through centralized bidding transactions. It details the number of shares repurchased, the proportion of total shares, prices, and total funds used. The document references regulatory guidelines on share repurchases and states the company's compliance and future plans. It is not a full financial report, earnings release, or management discussion, but a specific update on share repurchase activity. Therefore, it fits the category of Transaction in Own Shares (POS). The document length is short and focused solely on share repurchase progress, confirming this classification.
2022-04-22 Chinese
金宇生物技术股份有限公司关于终止实施2020年限制性股票激励计划并回购注销限制性股票的公告
Transaction in Own Shares Classification · 95% confidence The document is a detailed announcement from a company about terminating its 2020 restricted stock incentive plan and repurchasing and canceling restricted shares. It includes specifics about the number of shares, prices, board and supervisory approvals, legal opinions, and the impact on share capital structure. The content focuses on corporate governance actions related to stock incentives and share repurchases, not on financial results or earnings. It is not a full annual or interim report, nor an earnings release or investor presentation. It is a formal announcement about capital changes related to share repurchase and cancellation of restricted stock. Therefore, the document fits best under the category of Transaction in Own Shares (POS), which covers share repurchase/issuance announcements.
2022-04-21 Chinese
金宇生物技术股份有限公司关于续聘会计师事务所的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of an accounting firm (致同会计师事务所) as the company's auditor for the 2022 fiscal year. It details the auditor's background, qualifications, independence, audit fees, and the approval process by the board and independent directors. There are no actual financial statements or audit reports included, nor is this a full annual or interim report. The document serves as a formal announcement of the auditor appointment and related procedural approvals, not the audit report itself. Therefore, it fits best under the category of Audit Report / Information (AR), which includes standalone audit-related announcements and information about audit firms and their appointment. FY 2022
2022-04-21 Chinese
金宇生物技术股份有限公司2021年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2021 年度内部控制评价报告' which translates to '2021 Annual Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2021, including financial and non-financial internal control defects, audit opinions, and corrective actions. The content is focused on internal control evaluation rather than full financial statements or annual performance. It is a standalone report on internal control evaluation, not a full annual report (10-K) or audit report of financial statements. The document length is 3991 characters, which is relatively short but contains substantive evaluation content, not just an announcement. This fits the category of Audit Report / Information (AR), which includes standalone audit reports and internal control evaluation results. Therefore, the appropriate classification is AR with high confidence. FY 2021
2022-04-21 Chinese
金宇生物技术股份有限公司独立董事关于第十届董事会第十六次会议相关事项的独立意见
Regulatory Filings
2022-04-21 Chinese
金宇生物技术股份有限公司二〇二一年度内部控制审计报告
Regulatory Filings
2022-04-21 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.